NCT00684190

Drug Interaction Study Between AZD3355 and Nexium

An Open, Randomised, Three Period Cross, Single Centre, Phase 1 Pharmacokinetic Interaction Study of the Reflux Inhibitor AZD3355 150 mg Bid and Esomeprazole 40 mg od After 7 Days of Treatment in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to evaluate if AZD3355 and Nexium interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.

Conditions

• Gastroesophageal Reflux Disease

Interventions

Type	Name	Description
DRUG	AZD3355	150 mg bid, oral, 7 days
DRUG	Esomeprazole	40 mg od, oral, 7 days

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-06-01
• Completion: 2008-06-01
• First posted: 2008-05-26
• Last updated: 2010-12-03

Locations

1 site across 1 country: Sweden